News
March 8, 2024
UPDATE: Investigational New Drug, ATA3219, Receives FDA Approval for Lupus Nephritis Treatment Study
The new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) was approved for study by the U.S. Food and Drug Administration. The first trial participants are expected to be enrolled in the second half of 2024. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.
See More:
Get Lupus Research Headlines Emailed to You
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.
The latest from Inside Lupus Research
News
New Study Finds Vitamin D Levels Could Influence Pregnancy Outcomes for Women with Systemic Lupus Erythematosus
News
UPDATE: Ventus Therapeutics Announces Positive Phase 1 Trial Results for Investigational Drug, VENT-03, for Lupus
News
GSK Set to Acquire CMG1A46 from Chimagen Biosciences
News
Scientists Identify Key Biomarkers That May Predict Low-Dose IL-2 Treatment Efficacy in People with Systemic Lupus Erythematosus